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Introduction 
Pleural and pericardial fibrosis may develop after 
asbestos exposure, following drug ingestion, e.g. 
practolol and methysergide and in some connective 
tissue diseases (1). Ergotamine is a natural ergot alka- 
loid with a similar chemical structure to methysergide. 
We describe a patient who developed pleural and 
pericardial fibrosis secondary to chronic ergotamine 
use. 
Case Reports 
A 70-year-old woman was admitted for investi- 
gation of persistent bilateral pleuritic chest pain and 
progressive breathlessness of 2 months duration. Her 
symptoms began 18 months previously with left sided 
chest pain which resolved spontaneously after a few 
weeks only to recur on the right side and follow a 
similar pattern. She denied weight loss, arthralgia, 
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Raynaud’s phenomenon and haemoptysis but had 
noted some non-specific malaise. 
There was no history of asbestos exposure and she 
had not smoked for 46 yr. Her only treatment had been 
half a ‘Migril’ tablet (ergotamine 2 mg, cyclizine 50 mg 
and caffeine 100 mg; Wellcome) on alternate days for 
30 yr. It was confirmed by her general practitioner that 
she had taken this treatment regularly but had never 
received methysergide or beta blockers. 
On examination she was not dyspnoeic, cyanosed or 
clubbed but was dull to percussion at the bases of both 
lungs, where auscultation revealed a few late inspira- 
tory crackles. The cardiovascular system was normal 
with a blood pressure of 140/84 and no paradox. Chest 
radiograph showed bilateral pleural thickening, 
worse on the left [Plate 1 (a)]. The plasma viscosity was 
raised to 1.97 mPas, but the full blood count, routine 
biochemistry, autoantibody screens and ECG were 
normal. Lung function tests showed a restrictive 
picture: FEV , 1.1 1 (58% predicted); FVC I.75 I 
(77% predicted); ratio 63%, total lung capacity 3.3 
(72% predicted); gas transfer 5 mmol min’ kPa- 
(74% predicted). Ultrasound of the thorax showeN d 
Fig. 1 (a) Chest radiograph at presentation. (b) Chest radiograph 7 months after stopping ergotamine. 
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Fig. 2 Computerized tomography of thorax illustrating the pericardial thickening (arrowed) 
small bilateral pleural effusions and computerized 
tomography confirmed bilateral pleural thickening 
along with marked pericardial thickening; no calcifi- 
cation or retroperitoneal fibrosis was seen and 
the lungs were normal (Plate 2). A CT guided 
cutting needle biopsy showed the pleura to be grossly 
thickened and fibrotic with little inflammatory cell 
infiltrate; there was no evidence of neoplasia. 
The ergotamine was discontinued with a prompt 
resolution of her chest pain and breathlessness. Over a 
7-month period she has remained well with no 
migraine. The plasma viscosity is now normal, the 
chest radiograph has gradually improved [Plate l(b)], 
dynamic lung volumes (FEV, 1.3 1, 71% predicted; 
FVC 2 1, 90% predicted) and total lung capacity 
(41, 87% predicted) have increased, although her 
transfer factor remains unaltered. 
Discussion 
Pleural and pericardial fibrosis are recognized after 
methysergide therapy (I). Despite having a similar 
chemical structure there are only four reports in the 
English language of ergotamine related pleural or 
pericardial fibrosis. In three of the cases there was a 
protracted history ofergotamine ingestion (3-5) while 
the fourth patient had only received treatment for 4 yr 
and had a large social exposure to asbestos, her hus- 
band dying of mesothelioma (6). Three individuals had 
a high ESR and unexplained anaemia at presentation 
and one had predominantly unilateral disease on chest 
X-ray. The results of computerized tomography were 
reported on one patient, bilateral pleural thickening 
being identified but no comment was made about the 
pericardium (5). 
Spirometry in two patients showed a restrictive 
pattern while reduced lung volumes were also found in 
two patients, one of whom had normal gas transfer. 
Pericardial disease was identified in only one of the 
patients after 10 yr of ergotamine therapy, which was 
not discontinued until she developed pleural problems 
9 yr later. All four patients underwent thoracotomy to 
obtain pleural tissue, histology showing non-specific 
fibrosis. 
Since stopping the ergotamine our patient has been 
symptom free, the plasma viscosity has fallen and both 
the pulmonary function tests and chest radiograph 
have improved. A similar resolution of symptoms and 
investigations have been described in the previous four 
case reports (3-6). 
It has been suggested that fibrosis develops because 
of reduced tissue blood supply secondary to vaso- 
constriction (7), although this seems unlikely given 
that the potential for vasoconstriction is much greater 
with ergotamine than methysergide. The high ESR on 
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presentation and improvement in both symptoms and 2. 
investigations after stopping ergotamine suggests that 
a hypersensitivity type reaction is more likely (6,s). 3, 
This may explain why the fibrosis improves on cess- 
ation of ergotamine therapy, although the pleural tis- 
sue from the patient we describe showed little evidence 4. 
of an inflammatory process. 
Lepage-Savary D, Vallieres A. Ergotamine as a possible 
cause of retriperotoneal fibrosis. Clin Pharm 1982; 1: 
179-180. 
Bilateral pleural thickening is an infrequent finding 
in asymptomatic individuals attending for a chest 
5, 
X-ray. The cause is usually previous asbestos exposure 
or connective tissue disease, but in some cases the 6. 
aetiology is unknown. This case report highlights the 
importance of a careful drug history in such patients. 
I. 
References 
Taal BG, Spierings ELH, Hilvering C. Pleuropulmonary 
fibrosis associated with chronic and excessive intake of 
ergotamine. Thorax 1983; 38: 396398. 
Robert M, Derbaudrenghein JP, Blampain JP, Lamy F, 
Meyer P. Fibrotic changes associated with long term 
ergotamine therapy. NEngl J Med 1984; 311: 601-602. 
Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique 
J. Pleural and retroperitoneal fibrosis from dihydro- 
ergottamine. N Enal J Med 1989: 321: 1760. 
Zilstra EE, Wilson JHP, Ouwendijk RJTh. Pleural fibro- 
sis associated with ergotamine therapy. Eur J Intern Med 
1990; 1: 245247. 
Spierings ELH, Saxena PR. Antimigraine drugs and 
cranial arteriovenous shunting in the cat. Neurology 1989; 
30: 696701. 
I. Graham JR, Suby HL, LeCompte PR, Sadowsky NL. 8. Hodel Ch, Griffith R. Inability to reproduce retroperito- 
Fibrotic disorders associated with methysergide therapy neal fibrosis in animal toxicity studies with methysergide. 
for headache. N Engl J Med 1966; 274: 359-368. Int Congr Series 1913; 3 17-322. 
